StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $2.00 price target on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Price Performance

Senseonics stock opened at $0.42 on Tuesday. Senseonics has a 12 month low of $0.37 and a 12 month high of $0.75. The stock’s 50 day moving average is $0.42 and its 200-day moving average is $0.48. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. The company has a market capitalization of $222.97 million, a price-to-earnings ratio of -3.00 and a beta of 0.82.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. Equities research analysts expect that Senseonics will post -0.13 EPS for the current year.

Institutional Trading of Senseonics

Large investors have recently bought and sold shares of the business. RPO LLC acquired a new stake in Senseonics during the 4th quarter worth about $37,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Senseonics in the 1st quarter valued at about $91,000. Virtu Financial LLC acquired a new stake in shares of Senseonics in the 1st quarter valued at about $162,000. Cubist Systematic Strategies LLC grew its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the period. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.